Eight R&D and manufacturing campuses in the United States and China, staffed by more than 2,200 scientists, serve over 1,500 active customers from a headquarters in Irvine, California. Work extends beyond small molecules to peptides, oligonucleotides, and antibody drug conjugates, with named platforms for PROTAC degraders, DNA-encoded libraries, compound management, and IND-enabling packages. Oncology pharmacology offers PDX, CDX, orthotopic, syngeneic, humanized mouse, and CAR-T and CAR-NK models, and separate groups run MASH, respiratory, neuroscience, metabolic, and safety pharmacology studies. DMPK teams handle in vitro ADME, in vivo PK and TK, bioanalysis, and exploratory toxicity in rodents, dogs, and monkeys. Process R&D uses flow chemistry, sugar chemistry, and process safety assessment, while formulation work applies hot melt extrusion, spray dried dispersion, and amorphous solid dispersion to solubility problems, with IND filings supported for the FDA, NMPA, and other agencies.
BioDuro
BioDuro-Sundia is a premier global contract research, development, and manufacturing organization (CRDMO) providing fully integrated drug discovery and development services. Covering small molecules and biologics from discovery chemistry and formulation development to clinical trial manufacturing, BioDuro-Sundia helps partners streamline timelines and de-risk drug candidates.
